Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011
Dispatch

Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan

Chun-Hsing Liao, Yu-Tsung Huang, Chih-Cheng Lai, Cheng-Yu Chang, Fang-Yeh Chu, Meng-Shiuan Hsu, Hsin-Sui Hsu, and Po-Ren Hsueh
Author affiliations: Author affiliations: Far Eastern Memorial Hospital, Taipei, Taiwan (C.-H. Liao, C.-C. Lai, C.-Y. Chang, F.-Y. Chu, M.-S. Hsu, H.-S. Hsu); National Taiwan University College of Medicine, Taipei (Y.-T. Huang, P.-R. Hsueh)

Main Article

Table A1

Distribution and clinical characteristics of 225 patients with Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*

Characteristic K1, n = 41 K2, n = 37 Non–K1/K2, n = 147 Univariate analysis (K1 vs. non– K1/K2)
Univariate analysis (K2 vs. non–K1/K2)
OR (95% CI) p value OR (95% CI) p value
Age, y 61.8 ± 13.8 58.6 ± 15.1 62.2 ± 16.4 1.00 (0.98–1.02) 0.88 0.99 (0.96–1.01) 0.23
M:F 26:15 24:13 95:52 0.95 (0.46–1.95) 0.89 1.01 (0.58–2.15) 0.98
Source of patients
Emergency department 36 (87.8) 22 (59.5) 75 (51.0) 6.91 (2.57–18.60) <0.001 1.41 (0.68–2.93) 0.36
Ward 5 (12.2) 8 (21.6) 47 (17.0) 0.30 (0.11–0.80) 0.017 0.59 (0.25–1.38) 0.22
Intensive care unit 0 7 (18.9) 25 (32.0) NA NA 1.14 (0.45–2.88) 0.78
Severity of disease (McCabe classification)
Nonfatal 31 (75.6) 24 (64.9) 79 (53.7) 2.67 (1.22–5.84) 0.014 1.59 (0.75–3.36) 0.23
Ultimately fatal 7 (17.1) 8 (21.6) 50 (34.0) 0.40 (0.17–0.97) 0.041 0.54 (0.23–1.26) 0.15
Rapidly fatal 3 (7.3) 5 (13.5) 18 (12.3) 0.57 (0.16–2.02) 0.38 1.12 (0.39–3.24) 0.84
Pittsburgh bacteremia score 2.7 ± 3.1 5.0 ± 5.3 4.4 ± 4.7 0.90 (0.81–0.99) 0.032 1.03 (0.95–1.10) 0.50
Underlying illness, condition, or value
Diabetes mellitus 19 (46.3) 14 (37.8) 54 (36.7) 1.49 (0.74–2.99) 0.27 1.05 (0.50–2.21) 0.90
End-stage renal disease 1 (2.4) 1 (2.7) 8 (5.4) 0.43 (0.05–3.58) 0.44 0.48 (0.06–3.99) 0.50
Heart disease 4 (9.8) 8 (21.6) 33 (22.5) 0.37 (0.12–1.12) 0.08 0.95 (0.40–2.28) 0.91
Stroke 4 (9.8) 3 (8.1) 21 (14.3) 0.65 (0.21–2.01) 0.45 0.53 (0.15–1.88) 0.33
Active malignancy 5 (12.2) 6 (16.2) 29 (19.7) 0.57 (0.20–1.57) 0.27 0.79 (0.30–2.07) 0.63
Liver cirrhosis 4 (9.8) 6 (16.2) 23 (15.7) 0.58 (0.19–1.79) 0.35 1.04 (0.39–2.78) 0.93
Surgery within 3 mo 4 (9.8) 8 (21.6) 45 (30.6) 0.25 (0.08–0.73) 0.011 0.63 (0.27–1.47) 0.28
CT within 3 mo 2 (4.9) 3 (8.1) 16 (10.9) 0.42 (0.09–1.91) 0.26 0.72 (0.20–2.62) 0.62
Creatinine level, mg/dL 1.7 ± 1.9 1.6 ± 1.4 1.9 ± 2.0 0.93 (0.76–1.13) 0.45 0.91 (0.73–1.14) 0.42
Albumin level, g/dL† 2.8 ± 0.6 2.7 ± 0.6 2.7 ± 0.7 1.13 (0.57–2.23) 0.74 0.85 (0.43–1.71) 0.65
Type of infection
Primary bacteremia 11 (26.8) 12 (32.4) 39 (26.5) 1.02 (0.47–2.22) 0.97 1.33 (0.61–2.90) 0.47
Respiratory tract 4 (9.8) 6 (16.2) 30 (20.4) 0.42 (0.14–1.28) 0.13 0.76 (0.29–1.98) 0.57
Urinary tract 2 (4.9) 3 (8.1) 30 (20.4) 0.20 (0.05–0.88) 0.033 0.34 (0.10–1.20) 0.09
Biliary tract 3 (7.3) 3 (8.1) 26 (17.7) 0.37 (0.11–1.28) 0.12 0.41 (0.12–1.44) 0.16
Liver abscess 19 (46.3) 5 (13.5) 6 (4.1) 20.3 (7.31–56.40) <0.001 3.67 (1.06–12.8) 0.041
Intraabdominal 1 (2.4) 5 (13.5) 8 (5.4) 0.43 (0.05–3.58) 0.44 2.72 (0.83–8.85) 0.10
Catheter related 0 0 6 (4.1) NA NA NA NA
Soft tissue 0 1 (2.7) 2 (1.36) NA NA 2.01 (0.18–22.83) 0.57
Meningitis 1 (2.4) 2 (5.4) 0 NA NA NA NA
TTP, h 14.4 ± 18.5 12.1 ± 12.1 13.1 ± 16.3 1.00 (0.99–1.02) 0.65 1.00 (0.97–1.02) 0.75
TTP<7 h 6 (14.6) 7 (18.9) 32 (21.8) 0.62 (0.24–1.59) 0.32 0.84 (0.34–2.09) 0.71
14-d mortality rate 4 (9.8) 10 (27.0) 35 (23.8) 0.35 (0.12–1.04) 0.058 1.19 (0.52–2.69) 0.68
In-hospital mortality rate 6 (14.6) 16 (43.2) 51 (34.7) 0.32 (0.13–0.82) 0.017 1.43 (0.70–2.99) 0.34
ESBL producer 0 0 4 (2.7) NA NA NA (NA) NA
Effective empirical agent 35 (85.4) 36 (97.3) 138 (93.9) 0.38 (0.13–1.14) 0.08 2.35 (0.29–19.14) 0.43

*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.

Main Article

Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external